ACM
CTMX icon

ADAR1 Capital Management’s CytomX Therapeutics CTMX Stock Holding History

ADAR1 Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100,000
Closed -$426K – 316
2025
Q4 		$426K Buy
+100,000
New +$380K 0.03% 196

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ADAR1 Capital Management's CTMX Position: Q1 2026 in Review

ADAR1 Capital Management reduced its CytomX Therapeutics (CTMX) stake by 18% in Q1 2026, selling an estimated $3.92M and leaving 3,410,190 shares worth $16M. The position accounts for 0.94% of the portfolio, ranked #21.

ADAR1 Capital Management first reported a position in CTMX in Q1 2024 and has held it in 9 quarters since. The position peaked at $17.8M in Q4 2025. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • ADAR1 Capital Management held 3,410,190 shares of CytomX Therapeutics worth $16M as of Q1 2026.
  • ADAR1 Capital Management sold 772,579 CytomX Therapeutics shares in Q1 2026, an estimated $3.92M.
  • CytomX Therapeutics made up 0.94% of ADAR1 Capital Management's portfolio in Q1 2026, its #21 holding.
  • ADAR1 Capital Management first reported a position in CytomX Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • ADAR1 Capital Management's CytomX Therapeutics position peaked at $17.8M in Q4 2025.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.